Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03847090 · ClinicalTrials.gov registry record · Phase 3
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
A Phase 3 study, sponsored by Allena Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
NCT03847090: Clinical Trial Phase 3 study, sponsored by Allena Pharmaceuticals.
NCT03847090 is a Phase 3 study that was terminated before completion, run by Allena Pharmaceuticals. The registered enrollment target is 92 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03847090, a Phase 3 study, was terminated before completion, sponsored by Allena Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.
Primary Outcome
Efficacy will be assessed based on percent change from baseline to the average across Weeks 1 to 4, derived from all 24-hour collections during Weeks 1 to 4 on treatment
Interventions
- DRUG Placebo
- DRUG Reloxaliase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2022-05-19 |
| Phase | Phase 3 |
Why NCT03847090 stopped before completion
NCT03847090 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03847090 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03847090 about?
NCT03847090 is a clinical study titled "Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria". The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.
What is the current status of trial NCT03847090?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2019-08-26. Estimated completion is 2022-05-19.
What interventions are being tested in trial NCT03847090?
The interventions under investigation include: Placebo (DRUG), Reloxaliase (DRUG).
Who is sponsoring clinical trial NCT03847090?
This trial is sponsored by Allena Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03847090's enrollment target sits among peer trials
92 1723rd of 2000 higher than 277 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI